CARTO PRIME™ Module
CARTO™ 3 System and the CARTO PRIME™ Module offers advancement in 3D mapping technology. From signals to diagnosis, across a wide range of electrophysiology procedures, we are re-framing the future of electrophysiology.
.png?width=3840&quality=90&format=webp)
Clinical evidence
93.3%
Cases successfully identified the mechanism of scar-related atrial tachycardias1
In a prospective multi-center study (n=20), Coherent Mapping cases.
9mm
Average position shift between LAT Hybrid PVC Mapping Location and its associated Standard PVC Mapping Location2
In a prospective multi-center study (n=18), LAT Hybrid cases.
Features & benefits
.png?width=3840&quality=90&format=webp)
Coherent Mapping
Coherent Mapping may simplify the diagnosis of scar‐related complex atrial arrhythmia by applying physiological constraints on LAT information. It improves accuracy of ablation site identification.1
Features:
- Conduction ID
- Conduction velocity vectors
- Conduction barrier zones; such as scar, slow conduction and anatomical structures
.png?width=3840&quality=90&format=webp)
Parallel Mapping and Map Replay
- Real-time acquisition: Use Parallel Mapping to create a group up to 4 maps and assign each one a different set of acquisition filters. During continuous acquisition, EA points are acquired to the appropriate map.3
- Recalculate an existing map: The Map Replay option creates a new map by recalculating an existing map according to different acquisition filters.3
- Retrospectively acquire points from a specific time in the study: Define a time frame in the CARTOREPLAY™ Module Timeline and acquire points according to the acquisition filters in the current Active Map.3
.png?width=3840&quality=90&format=webp)
CARTOFINDER™ Module
The CARTOFINDER™ Module provides automatic analysis of multiple, simultaneous intracardiac (IC) signals and enables the creation of high density dynamic maps.3
.png?width=3840&quality=90&format=webp)
LAT Hybrid
Transient changes in the heart rhythm, such as Premature Ventricular Contraction (PVC), can lead to catheter displacement compared to normal sinus activation. LAT Hybrid maps provide a solution for PVC mapping by creating a hybrid point: the coloring reflects the LAT value during PVC rhythm, and the location corresponds to the location during sinus rhythm.3
Supporting documentation
Webpage
Webpage
Related products
CARTO ELEVATE™ Module
CARTO™ 3 System V8 brings advanced mapping capabilities with enhanced signal analysis tools, improved substrate characterization and utilization of ultrasound technology.
CARTOSOUND™ FAM Module
Powered by Artificial Intelligence, the CARTOSOUND™ FAM Module reconstructs the left atrial (LA) anatomy on the CARTO™ 3 System with a few rotations of your ultrasound catheter, eliminating the need for manual contouring.
References
- Anter E et al. Activation Mapping with Integration of Vector and Velocity Information Improves the Ability to Identify the Mechanism and Location of Complex Scar Related Atrial Tachycardias. Circ Arrhythm Electrophysiol. 2018;11:e006536.
- Tom De Potter, Konstantinos Iliodromitis, Tal Bar-On, Etel Silva Garcia, Joris Ector, Premature ventricular contractions cause a position shift in 3D mapping systems: analysis, quantification, and correction by hybrid activation mapping, EP Europace, Volume 22, Issue 4, April 2020, Pages 607–612
- CARTO 3 System Instructions for Use. UG-5400-0082H (04A), November 2025.
- Steyers III CM et al. Ablation using 3D maps adjusted for spatial displacement of premature ventricular complexes relative to sinus beats: Improving precision by correcting for the shift. J Cardiovasc Electrophysiol. 2019;1–7.
Important information: Prior to use, refer to the instructions for use supplied with this device for indications, contraindications, side effects, warnings and precautions. Caution: US law restricts this device to sale by or on the order of a physician.
The THERMOCOOL SMARTTOUCH™ SF Catheter is indicated for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation (AF) and for drug refractory recurrent symptomatic persistent AF (continuous AF > 7 days but < 1 year), refractory or intolerant to at least 1 Class I or III AAD, when used with the CARTO™ 3 System.
Last Updated on 09/25/2025.
US_ELP_NAVI_201219.1